References
- Bail S, Swerdel M, Liu H, Jiao X, Goff LA, Hart RP, Kiledjian M. (2010). Differential regulation of microRNA stability. RNA 16:1032–1039.
- Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297.
- Bartel DP. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136:215–233.
- Chen XM. (2009). MicroRNA signatures in liver diseases. World J Gastroenterol 15:1665–1672.
- Choudhury D, Ahmed Z. (1997). Drug-induced nephrotoxicity. Med Clin North Am 81:705–717.
- Fabbri M, Croce CM, Calin GA. (2008). MicroRNAs. Cancer J 14:1–6.
- Fukushima T, Hamada Y, Yamada H, Horii I. (2007). Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride–regulating role of micro-RNA for RNA expression. J Toxicol Sci 32:401–409.
- Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. (2008). miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 48:648–656.
- Grosshans H, Slack FJ. (2002). Micro-RNAs: small is plentiful. J Cell Biol 156:17–21.
- Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G. (2010). A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28:655–661.
- He L, Hannon GJ. (2004). MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531.
- Ho J, Ng KH, Rosen S, Dostal A, Gregory RI, Kreidberg JA. (2008). Podocyte-specific loss of functional microRNAs leads to rapid glomerular and tubular injury. J Am Soc Nephrol 19: 2069–2075.
- Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309:1577–1581.
- Kren BT, Wong PY, Sarver A, Zhang X, Zeng Y, Steer CJ. (2009). MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis. RNA Biol 6:65–72.
- Kroh EM, Parkin RK, Mitchell PS, Tewari M. (2010). Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298–301.
- Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. (2002). Identification of tissue-specific microRNAs from mouse. Curr Biol 12:735–739.
- Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. (2003). Prediction of mammalian microRNA targets. Cell 115:787–798.
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518.
- Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK. (2011). Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54:1767–1776.
- Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 106:4402–4407.
- Weickmann JL, Glitz DG. (1982). Human ribonucleases. Quantitation of pancreatic-like enzymes in serum, urine, and organ preparations. J Biol Chem 257:8705–8710.
- Wong QW, Lung RW, Law PT, Lai PB, Chan KY, To KF, Wong N. (2008). MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 135:257–269.
- Yu Z, Hecht NB. (2008). The DNA/RNA-binding protein, translin, binds microRNA122a and increases its in vivo stability. J Androl 29:572–579.